Sept 29 (Reuters) – Novo Nordisk A/S: * NOVO'S OZEMPIC (SEMAGLUTIDE) 2 MG ASSOCIATED WITH LOWER RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (DEATH, HEART ATTACK, AND STROKE) IN ADULTS WITH TYPE 2
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)